Table 2 Univariate and multivariate COX analysis for survival analysis of TCGA CN-AML patients
From: High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia
Parameter | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HR | 95%CI | P | HR | 95%CI | P | |
Age | 1.026 | 1.008–1.044 | 0.003 | 1.031 | 1.011–1.051 | 0.002 |
Gender | 1.052 | 0.609–1.817 | 0.765 |  |  |  |
Bone marrow blasts | 0.996 | 0.983–1.009 | 0.507 |  |  |  |
WBC counting | 0.995 | 0.988–1.002 | 0.137 | 0.998 | 0.990–1.006 | 0.566 |
Hemoglobin | 0.999 | 0.826–1.208 | 0.957 |  |  |  |
Platelet counting | 1.004 | 0.999–1.009 | 0.040 | 1.005 | 0.998–1.011 | 0.157 |
FLT3 mutation | 2.6 | 1.461–4.631 | 0.001 | 1.881 | 0.920–3.848 | 0.084 |
KRAS mutant | 1.232 | 0.381–3.980 | 0.728 |  |  |  |
CEBPA mutant | 0.624 | 0.248–1.572 | 0.317 |  |  |  |
TET2 mutant | 0.8 | 0.317–2.018 | 0.636 |  |  |  |
TP53 mutant | 1.938 | 0.264–14.248 | 0.516 |  |  |  |
NRAS mutant | 0.24 | 0.033–1.742 | 0.158 | 0.282 | 0.036–2.234 | 0.231 |
IDH1 mutant | 0.519 | 0.185–1.451 | 0.211 |  |  |  |
IDH2 mutant | 1.047 | 0.506–2.166 | 0.900 |  |  |  |
RUNX1 mutant | 2.22 | 1.089–4.524 | 0.028 | 2.233 | 0.969–5.145 | 0.059 |
NPM1 mutant | 1.08 | 0.623–1.868 | 0.785 |  |  |  |
HSPA8 | 2.042 | 1.068–3.907 | 0.031 | 2.408 | 1.080–5.368 | 0.032 |